| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/21/2022 | 892.37% | HC Wainwright & Co. | $14 → $13 | Maintains | Buy |
| 11/08/2022 | 52.67% | SVB Leerink | $3 → $2 | Maintains | Market Perform |
| 05/19/2022 | 968.7% | HC Wainwright & Co. | $19 → $14 | Maintains | Buy |
| 03/23/2022 | 129.01% | SVB Leerink | $7 → $3 | Maintains | Market Perform |
| 01/19/2022 | 281.68% | Goldman Sachs | $28 → $5 | Downgrades | Buy → Neutral |
| 01/13/2022 | 1350.38% | HC Wainwright & Co. | $25 → $19 | Maintains | Buy |
| 11/10/2021 | 434.35% | SVB Leerink | $8 → $7 | Maintains | Market Perform |
| 10/21/2021 | 510.69% | SVB Leerink | $18 → $8 | Downgrades | Outperform → Market Perform |
| 09/20/2021 | 2113.74% | Truist Securities | $40 → $29 | Maintains | Buy |
| 09/20/2021 | 1808.4% | HC Wainwright & Co. | $37 → $25 | Maintains | Buy |
| 09/17/2021 | 739.69% | Wedbush | $45 → $11 | Downgrades | Outperform → Neutral |
| 08/06/2021 | 2266.41% | SVB Leerink | $34 → $31 | Maintains | Outperform |
| 06/24/2021 | 2190.08% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
| 03/11/2021 | 2495.42% | SVB Leerink | $41 → $34 | Maintains | Outperform |
| 12/14/2020 | 2724.43% | HC Wainwright & Co. | $32 → $37 | Maintains | Buy |
| 11/30/2020 | 2800.76% | Roth Capital | $35 → $38 | Maintains | Buy |
| 08/21/2020 | — | Mizuho | Initiates Coverage On | → Buy | |
| 08/13/2020 | 2953.44% | Truist Securities | → $40 | Initiates Coverage On | → Buy |
| 08/13/2020 | 2342.75% | HC Wainwright & Co. | $33 → $32 | Maintains | Buy |
| 08/12/2020 | 1808.4% | SVB Leerink | $26 → $25 | Maintains | Outperform |
| 08/12/2020 | 2571.76% | Piper Sandler | → $35 | Initiates Coverage On | → Overweight |
| 07/27/2020 | 2571.76% | Roth Capital | $16 → $35 | Upgrades | Neutral → Buy |
| 07/27/2020 | 2419.08% | HC Wainwright & Co. | $19 → $33 | Maintains | Buy |
| 11/04/2019 | 1350.38% | HC Wainwright & Co. | → $19 | Initiates Coverage On | → Buy |
| 05/31/2019 | 1121.37% | Roth Capital | → $16 | Initiates Coverage On | → Neutral |
| 03/11/2019 | 2037.4% | Wedbush | → $28 | Initiates Coverage On | → Outperform |
| 03/11/2019 | 2724.43% | BMO Capital | → $37 | Initiates Coverage On | → Outperform |
| 03/11/2019 | 2266.41% | Jefferies | → $31 | Initiates Coverage On | → Buy |
What is the target price for TCR2 Therapeutics (TCRR)?
The latest price target for TCR2 Therapeutics (NASDAQ: TCRR) was reported by HC Wainwright & Co. on November 21, 2022. The analyst firm set a price target for $13.00 expecting TCRR to rise to within 12 months (a possible 892.37% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TCR2 Therapeutics (TCRR)?
The latest analyst rating for TCR2 Therapeutics (NASDAQ: TCRR) was provided by HC Wainwright & Co., and TCR2 Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for TCR2 Therapeutics (TCRR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TCR2 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TCR2 Therapeutics was filed on November 21, 2022 so you should expect the next rating to be made available sometime around November 21, 2023.
Is the Analyst Rating TCR2 Therapeutics (TCRR) correct?
While ratings are subjective and will change, the latest TCR2 Therapeutics (TCRR) rating was a maintained with a price target of $14.00 to $13.00. The current price TCR2 Therapeutics (TCRR) is trading at is $1.31, which is out of the analyst's predicted range.